ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,464.62
-0.16%
Dow Jones
39,150.33
0.04%
US Dollar vs MXN
18.1108
0.00%
Brent Oil
84.39
0.00%
Bitcoin
64,112.18
-0.21%
Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. I MAB (IMAB)

  7. I MAB (IMAB) Noticias

IMAB

I MAB (IMAB)

I MAB
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:IMAB
FechaHoraFuenteTítuloSímboloCompañía
06/06/202406:14Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IMABI MAB
06/06/202406:00PR Newswire (US)I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical OfficerNASDAQ:IMABI MAB
05/06/202406:00PR Newswire (US)I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal CancersNASDAQ:IMABI MAB
30/05/202416:33Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:IMABI MAB
23/05/202416:05GlobeNewswire Inc.I-Mab Announces Encouraging Phase 1 Clinical Data of PD-L1x4-1BB Bispecific Antibody Ragistomig at ASCO 2024NASDAQ:IMABI MAB
22/05/202406:00PR Newswire (US)I-Mab to Participate at the Jefferies Global Healthcare ConferenceNASDAQ:IMABI MAB
30/04/202406:00PR Newswire (US)I-MAB Filed 2023 Annual Report on Form 20-FNASDAQ:IMABI MAB
05/04/202406:00PR Newswire (US)I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:IMABI MAB
02/04/202415:01PR Newswire (US)I-Mab Announces Closing of the Divestiture of Business Operations in ChinaNASDAQ:IMABI MAB
14/03/202416:00PR Newswire (US)I-Mab Reports Full Year 2023 Financial Results and Business UpdateNASDAQ:IMABI MAB
09/02/202415:01Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:IMABI MAB
08/02/202405:07Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:IMABI MAB
07/02/202405:00PR Newswire (US)I-Mab Signs Agreement to Divest its Assets and Business Operations in ChinaNASDAQ:IMABI MAB
06/02/202419:55Edgar (US Regulatory)Form SCHEDULE 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:IMABI MAB
02/01/202416:08Dow Jones NewsADRs Slump; FLJ Group Declines 21%NASDAQ:IMABI MAB
01/12/202313:41Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:IMABI MAB
06/11/202307:00PR Newswire (US)I-Mab Announces Participation at Jefferies and Piper Conferences in NovemberNASDAQ:IMABI MAB
02/11/202307:00PR Newswire (US)Felzartamab Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for Primary Membranous Nephropathy (PMN)NASDAQ:IMABI MAB
01/11/202307:00PR Newswire (US)I-Mab Announces Poster Presentations of 4-1BB Bispecific Antibody Portfolio at SITC 2023NASDAQ:IMABI MAB
16/10/202307:00PR Newswire (US)I-Mab Announces Phase 1 Data of Givastomig at ESMO 2023NASDAQ:IMABI MAB
10/10/202307:00PR Newswire (US)I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1BB Bispecific Antibody TJ-L14B/ABL503NASDAQ:IMABI MAB
05/09/202307:00PR Newswire (US)I-Mab Announces Upcoming Participation at September ConferencesNASDAQ:IMABI MAB
17/08/202305:00PR Newswire (US)I-Mab Provides Mid-Year 2023 Financial Results, Business and Corporate UpdatesNASDAQ:IMABI MAB
08/08/202307:00PR Newswire (US)I-Mab to Report Mid-Year 2023 Financial Results, Business and Corporate Updates on August 17, 2023NASDAQ:IMABI MAB
05/07/202307:00PR Newswire (US)I-Mab Announces Publication of Claudin18.2 x 4-1BB Bispecific Antibody Givastomig in JITCNASDAQ:IMABI MAB
22/06/202307:40Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:IMABI MAB
22/06/202307:00PR Newswire (US)I-Mab Announces the Appointment of Raj Kannan as CEONASDAQ:IMABI MAB
25/05/202316:01PR Newswire (US)I-Mab Announces Encouraging Phase 1b/2 Study Results of Patients with Advanced NSCLC Receiving Uliledlimab and Toripalimab Combination Therapy at ASCO 2023NASDAQ:IMABI MAB
01/05/202307:00PR Newswire (US)I-MAB Filed 2022 Annual Report on Form 20-FNASDAQ:IMABI MAB
01/05/202305:57Edgar (US Regulatory)Annual and Transition Report (foreign Private Issuer) (20-f)NASDAQ:IMABI MAB
 Showing the most relevant articles for your search:NASDAQ:IMAB

Su Consulta Reciente

LSE
15QQ
Bp Cap
NYSE
IVAN
Ivanhoe Capital Acquisit...
LSE
89QO
ASX
HCL
HighCom
BIT
P204H8
NLBNPIT204H8 20991231 43...
BIT
NSCIT0052174
Italian Republic
BOV
RPAD6F
ALFA PNB
TG
A1Z810
Deutsche Bahn Finance BV
LSE
82OW
Resid.mtg 8res4
AQEU
MCP
Lvmh Moet Hennessy Louis...
USOTC
BTTC
Bitech Technologies (QB)
USOTC
CKSNF
Vesuvius (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados